The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Recent Trials Investigated Targeted Therapies for Systemic Sclerosis

Recent Trials Investigated Targeted Therapies for Systemic Sclerosis

May 18, 2019 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

SNOWMASS VILLAGE, COLO.—Data from three recent trials in systemic sclerosis (scleroderma) provide information on a number of important issues related to screening and treatment. First presented at the 2018 ACR/ARHP Annual Meeting, the phase 2/3 trials assessed the safety and efficacy of targeted agents to treat patients with systemic sclerosis.1-3

You Might Also Like
  • More Effective Antifibrotic Therapies for Systemic Sclerosis in Development; Adverse Events A Concern
  • Stem Cell Transplantation Shown to Improve Outcomes in Systemic Sclerosis
  • ANCA-Associated Vasculitis in Systemic Sclerosis
Explore This Issue
May 2019
Also By This Author
  • Management of Inflammatory Myositis: Options for Refractory Disease & New Therapies Discussed

In a follow-up presentation at the 2019 ACR Winter Rheumatology Symposium, Dinesh Khanna, MD, MSc, Frederick G.L. Huetwell Professor of Rheumatology, professor of internal medicine in the Division of Rheumatology, at the University of Michigan, Ann Arbor, and director of the University of Michigan Scleroderma Program, discussed key points highlighted by all three trials (see Table 1, below).

Table 1: Key Findings from Recent Trials on Targeted Therapy for Systemic Sclerosis

(click for larger image) Table 1: Key Findings from Recent Trials on Targeted Therapy for Systemic Sclerosis

Lessons Learned

Dr. Khanna also discussed lessons learned from the trials about the potential for targeted scleroderma therapies.

One lesson is the importance of understanding the natural history of systemic sclerosis and recognizing that most complications involving the internal organs occur early in the disease. Organ involvement typically occurs two to five years after the first non-Raynaud’s phenomenon symptom and may include lung, heart and renal problems. 

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Because internal organ involvement in most patients is irreversible, Dr. Khanna emphasized the importance of screening patients to ensure early detection and treatment. Internal organ involvement not detected and treated early can be fatal. Cardiopulmonary involvement (i.e., lung fibrosis and pulmonary arterial hypertension) is the leading cause of mortality in these patients.

Dr. Khanna also stressed the need to closely follow patients in whom the initial workup is negative to ensure early detection of internal organ involvement should it present.

One controversial question raised in the session was how aggressively to screen for internal organ involvement given the risks of tests for lung fibrosis (chest computed tomography with the risk of radiation) and pulmonary arterial hypertension (right heart catheterization is invasive and carries rare risks). For Dr. Khanna, the benefits of aggressive early screening outweigh the risks. “Our center aggressively screens these patients as we believe that early screening and diagnosis lead to better outcome measures,” he said.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Data support this belief. Dr. Khanna discussed a study showing improved survival in patients in whom pulmonary arterial hypertension is detected at an early stage, compared with historical cohorts.5 However, he also emphasized that using an echocardiogram for screening for pulmonary hypertension is associated with a high rate of false negatives and consideration should be given to combining different non-invasive measures for screening.6

Finally, the trials provided information on which targeted therapies show promise in treating specific complications. Phase 2 and phase 3 data now show that tocilizumab benefits lung function in patients even with a negative modified Rodnan skin score, and phase 2 data show patient function is improved with abatacept.

An important discussion focused on data related to autologous stem cell transplantation and its viability as a treatment option for systemic sclerosis. Dr. Khanna presented recent trial data from the SCOT trial on the long-term efficacy of myeloablative autologous transplantation for severe scleroderma.7 The study found a significant survival benefit at 11 years in patients treated with autologous transplantation compared with those treated with cyclophosphamide (88% vs. 53%; P=0.01).7

A primary takeaway, says Dr. Khanna, is the importance of early referral for a transplant consultation before organ failure to allow for shared decision making with patients about treatment choice.

Pages: 1 2 | Single Page

Filed Under: Conditions, Scleroderma Tagged With: abatacept, organ failure, systemic sclerosis (SSc), tocilizumabIssue: May 2019

You Might Also Like:
  • More Effective Antifibrotic Therapies for Systemic Sclerosis in Development; Adverse Events A Concern
  • Stem Cell Transplantation Shown to Improve Outcomes in Systemic Sclerosis
  • ANCA-Associated Vasculitis in Systemic Sclerosis
  • Markers for Severe Gastrointestinal Dysmotility in Systemic Sclerosis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.